ARCHIVES

Patient Advocacy: Survivorship Programs Win Funds To form Model Programs

This article is from The Cancer Letter archive.

Vol. 22 No. 48 | December 13, 1996

Download PDF Visit The Full Archive

Related Articles

Clolar Approved for Pediatric Refractory/Relapsed ALL

January 28, 2005

September issue of Business & Regulatory Report included (8-page issue).

October 4, 2002

Arimidex Reduces Relapse Compared To Tamoxifen, Large Study Reports

December 28, 2001

NCI Plans Trials of Burzynski’s ‘Antineoplaston’; JAMA Report Says No Antitumor Activity In Tests

June 5, 1992

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

February 17, 2012

Crawford Testimony in 2002 Promised Job to Pazdur.

February 18, 2005